BCI (brain-computer interface) technology — in which neural signals are routed from a person’s head to a computer — was once the stuff of science fiction, but these days the technology represents a competitive corner of the tech industry. One of the companies racing to commercialize BCI is Neurable, which this week announced that it’s looking to license its “mind-reading” technology to consumer wearables.
Neurable specializes in “non-invasive” BCI, which distinguishes itself from firms like Neuralink—the Elon Musk-founded startup known for inserting computer chips directly into people’s skulls—in that its product doesn’t require users to undergo brain surgery to enjoy its benefits.
Neurable’s technology works through a combination of EEG sensors and signal processing that can scan a user’s brain activity, analyze it with AI, and provide information about a person’s cognitive performance.
In December, Neurable raised $35 million in a series A, which it plans to use to scale the commercialization of its technology. This week, the company announced that, as part of its expansion effort, it is looking to license its technology to a variety of consumer-facing companies.
The idea is that mind-reading tech (which can provide detailed data about how a person’s brain works while they’re engaged in various activities) could be integrated into wearables across a number of industries—including health and athletic products, productivity tools, and gaming. “Through Neurable’s licensing platform, OEMs can directly integrate its AI-powered brain-sensing technology into existing hardware, such as headphones, hats, glasses, and headbands, while maintaining full control over product design, user experience, and distribution,” the company said in a press release on Tuesday.
Neurable has already fostered partnerships with a number of companies to test out its effectiveness. This includes HP Inc.’s HyperX, a gaming brand, with which it created a headset designed to help gamers “level up their game play by optimizing focus and performance.” It has also partnered with a company called iMotions, a software platform that specializes in human behavior research, to assist with the company’s research initiatives.
In an interview, Neurable’s CEO Ramses Alcaide declined to say what new partnerships the company has in the works, but said that the company was seeking to expand its purview across a host of domains.
Techcrunch event
San Francisco, CA | October 13-15, 2026
“In the past, we were very specific about our partnerships,” Alcaide said, noting that Neurable tended to home in on a particular company to prove that a unique commercial application was worthwhile. Now that they know expectations can be met on a number of fronts, the startup is focused on scaling itself, he said.
“What we’re doing now is we’re basically saying, like, ‘Hey, we’ve demonstrated that we’re getting great traction’,” Alcaide said. “Like, let’s make this as ubiquitous as heart rate sensors on your wrist, right?”
Despite the “non-invasive” label, brain data is arguably a little bit more intimate than the information culled from a heart rate sensor, so what kind of privacy protections does a company like Neurable provide?
Alcaide said that the company ensures that user data is “protected and anonymized.” The company’s privacy policy provides a variety of different guidelines for when and how a user’s data might be accessed and used. “We make sure we follow HIPAA standards, like we’ve gone above and beyond where a lot of startups would be at our stage to make sure that we protect the data, we encrypt it, and that we anonymize it,” Alcaide said.
Does Neurable leverage a user’s neural data to train its AI software?, we asked. “We can with user consent, right?” said Alcaide. “But we do it in a very specific way.” That specific way involves asking the user whether their data can be used for the purposes of particular experiments, Alcaide said. “We are not collecting the data, just training on it willy nilly,” he said. In other words, this kind of data usage is quite targeted.
Alcaide said that his industry is at an “inflection point”—one wherein there finally exists “a real business model in neuro-technology that is scalable.” What comes after that inflection point is the big question.
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.
The Plateau State Ministry of Health, National Malaria Elimination Programme and Malaria Consortium has engaged media practitioners and key stakeholders ahead of the 2026 Seasonal Malaria Chemoprevention (SMC) campaign to boost public awareness and community participation in the fight against malaria.
The media parley, held at the Crispan Event Centre in Jos, brought together health professionals, development partners and journalists to strategise on the successful implementation of the campaign aimed at protecting children under five from malaria.
Speaking at the event, the Commissioner for Health, Dr. Nicholas Ba’amlong, described the media as a critical partner in malaria elimination, saying sustained public enlightenment remains key to the success of the intervention.
He said Plateau had made remarkable progress in malaria control, with prevalence dropping from 18.8 per cent in 2021 to 2.8 per cent in 2025 due to increased government commitment, effective implementation of the SMC programme and the support of development partners.
“The prevalence rate has dropped from 18.8 per cent in 2021 to 2.8 per cent in 2025, representing about an 87 per cent reduction. It shows that malaria elimination is possible, and with sustained support for the SMC programme, we can achieve zero malaria,” he said.
In his presentation, Project Manager of the IMPACT Project, Nrs. Ndak Andarawus, said the 2026 SMC campaign targets 1,007,652 eligible children across Plateau State.
He disclosed that over 11,500 health workers, supervisors, volunteer drug distributors and community leaders had been mobilised for the exercise, while trained volunteers would administer preventive malaria drugs through house-to-house visits supported by digital monitoring systems to ensure every eligible child is reached.
Andarawus said the programme had contributed significantly to the reduction of malaria prevalence in the state through strong government support, effective partnerships and active community participation.
Project Manager of Malaria Consortium, Dr. Mbwas Mashor, said the media engagement was organised to strengthen collaboration with journalists and stakeholders to improve public awareness and acceptance of the SMC campaign.
He explained that Seasonal Malaria Chemoprevention is a World Health Organisation (WHO)-recommended intervention that provides safe and effective preventive malaria medicines for children aged three to 59 months during the peak malaria transmission season.
“We want the media to strengthen public awareness, promote accurate information and support community acceptance of the SMC campaign so that every eligible child is protected,” Mashor said.
The Permanent Secretary of the Ministry of Health described the media parley as timely and urged journalists to sustain accurate reporting on malaria prevention to improve community participation and campaign success.
Also speaking, SBCC Consultant, Mr. Kaskida Yilyok, said the media plays a vital role in shaping public perception, combating misinformation and encouraging caregivers to ensure eligible children receive the preventive medicines.
Programme Officer, Miss Kachollom Gyang, stressed that safeguarding remains a key component of the SMC programme, saying staff, partners and volunteers are regularly trained to protect children and vulnerable adults from abuse and exploitation.
She added that the programme operates a zero-tolerance policy against abuse and encouraged members of the public to report any safeguarding concerns for prompt investigation.
The Plateau State Chairman of the Nigerian Medical Association (NMA), Dr. Yilji Kumtap, commended the Ministry of Health and the State Malaria Elimination Programme for the progress recorded in malaria control and pledged the association’s continued support.
Similarly, Pharm. Godwin Nimyel, representing the Plateau State Chairman of the Pharmacy Society of Nigeria (PSN), reaffirmed the society’s support for the programme, stressing the need for quality-assured medicines and strict regulation to eliminate substandard drugs.
Also, Dr. Molsat Emmanuel Sydney, representing the Plateau State Primary Health Care Board, lauded the Ministry of Health, the State Malaria Elimination Programme and Malaria Consortium for their efforts in reducing malaria, assuring of the board’s continued support for the SMC campaign at the grassroots.
The Zamfara State chapter of the African Democratic Congress, ADC, has reacted to the defection of Dr Aslam Aliyu to the All Progressives Congress, APC, saying she was not a duly registered member of the party in the state.
Aliyu, an ally of former Vice President Atiku Abubakar, had announced her resignation from the ADC, saying the party lacked a concrete plan to address Nigeria’s challenges.
However, in a statement issued by the party’s State Publicity Secretary, Abdulhakeem Umar, the ADC said its records showed that Aliyu neither possessed a valid membership card nor was she formally registered as a member in Zamfara State.
The party maintained that her defection would not affect its leadership, structure or operations in the state.
According to the statement, the ADC remains committed to working with loyal and duly registered members who share its vision and are prepared to contribute to the party’s growth.
It also stated that anyone not committed to the party’s constitution, ideals and objectives was free to leave.
“We also wish to make it clear that any other person who is not genuinely committed to the ideals, Constitution, and objectives of the ADC is free to follow the same path.
Our focus is on building a disciplined, united, and principled political party with members who are dedicated to its progress.